HK Stocks Midday: Hang Seng Up 0.83%, Innovative Pharma and Gas Turbine Stocks Lead Gains
Miles Bennett
The Hang Seng Index rose 0.83% to 23,542 at the July 6 midday close, driven by a drug-approval policy catalyst and AI-linked power-equipment momentum, while computing-hardware names diverged sharply — YOFC fell over 13%.
Why did innovative-drug stocks suddenly lead the board?
China's drug regulator published a draft to streamline cell-and-gene-therapy approvals — covering R&D incentives, faster reviews, and an expanded expert panel. This means → the lab-to-market timeline for novel drugs could shorten, and capital moved in immediately.
The Hang Seng Innovative Drug Index rose 2.99% at midday. Sino Biopharmaceutical gained 7%; Jinfang Medicine-B surged over 10%.
Company-level catalysts stacked on top: Innocare's in-house ADC drug ICP-B208 dosed its first patient, while Quanxin Biotech's CLD-423 injection won clinical approval and continued signing overseas licensing deals. In plain terms = policy tailwinds and pipeline progress arrived at the same time.
What is the logic behind AI-driven gas-turbine stocks?
AI data centers are driving a surge in power demand. Gas turbines — large units that generate electricity from natural gas — serve as a fast-deployment solution, and the sector's order books keep filling.
Dongfang Electric rose over 7%; Harbin Electric gained over 6%. Both are leading domestic turbine makers.
Wasion Holdings climbed over 9% after its subsidiary won a smart-meter tender from Mexico's Federal Electricity Commission, worth up to 695 million yuan in orders this year. This means → the beneficiaries extend beyond equipment OEMs into power-metering and overseas contracts.
What other single-stock catalysts stood out?
Deshih-B surged over 18% on the launch of iMedLoop, a global medical-imaging data platform covering more than 90% of clinical scenarios.
Zhida Technology jumped over 23%, expanding into charging-robot operations with strong overseas demand expectations.
H&H International Holdings rose over 16%; first-half revenue grew at a double-digit rate and adjusted net profit is expected to double.
China Ruyi gained over 5%, set to become the exclusive first-batch partner for WeChat Agent in cinema ticketing while pushing into collectible card games.
Why was computing hardware falling instead?
YOFC (长飞光纤光缆) dropped over 13% at midday, the session's steepest decline among notable names.
The core worry: growth in computing-power demand may be falling short of expectations. This reflects a rotation *within* the AI supply chain — capital shifting from upstream hardware toward downstream applications and power infrastructure.
Key watch for the afternoon session and beyond: whether the drug-policy catalyst can sustain a sector-wide rally, and when demand expectations for computing hardware will recover.
Content is for reference only, not financial advice.